Physician profile
Louis E Steinberg
NPI 1245235258
$11,282.67
in general payments reported to CMS, 2019-2025
23 companies · $1,791 in 2025
The $1,791 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,447 · 2020: $1,042 · 2021: $1,724 · 2022: $1,840 · 2023: $1,867 · 2024: $1,572 · 2025: $1,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,051 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,050.95 |
| Education | $179.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,085.20 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $1,755.03 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,070.05 | 2019-2025 | |
| Insmed, INC. | $965.27 | 2019-2025 | Arikayce |
| Mylan Specialty L.P. | $955.24 | 2019-2024 | Yupelri, Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $737.75 | 2019-2024 | Ofev |
| Grifols USA, LLC | $602.65 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $299.37 | 2019-2024 | Dupixent |
| United Therapeutics Corporation | $297.83 | 2019-2022 | |
| Viatris Specialty LLC | $260.73 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $246.78 | 2019 | |
| Verona Pharma, INC. | $228.58 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $202.80 | 2020-2024 | Acthar |
| Genentech USA, INC. | $150.00 | 2021 | |
| Merck Sharp & Dohme LLC | $106.72 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Electromed, INC. | $71.07 | 2022 | |
| Amgen INC. | $41.32 | 2021-2022 | |
| Circassia INC. | $35.46 | 2019 | |
| Covis Pharma Gmbh | $34.45 | 2022 | |
| Sunovion Pharmaceuticals INC. | $23.17 | 2020 | |
| Paratek Pharmaceuticals, INC. | $19.47 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Steinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.